Kumar Rajnish, Srivastava Janmejai Kumar, Singh Rachana, Siddiqui Mohammed Haris, Mansouri Rasha A, Abdulhakim Jawaher A, Bin-Jumah May N, Alkahtani Saad, Abdel-Daim Mohamed M, Uddin Md Sahab
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow, India.
Department of Bioengineering, Integral University, Lucknow, India.
Front Pharmacol. 2020 Oct 6;11:582025. doi: 10.3389/fphar.2020.582025. eCollection 2020.
The recent outbreak of the COVID-2019 (coronavirus disease 2019) due to the infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has realized the requirement of alternative therapeutics to mitigate and alleviate this lethal infection. These alternative therapies are effective when they are started at the initial stage of the infection. Some drugs that were used in previous other related infections SARS-CoV-2003 and Middle East respiratory syndrome coronavirus (MERS-CoV)-2012 could be potentially active against currently emerging SARS-CoV-2. This fact imparts some rationale of current interventions, in the absence of any specific therapeutics for SARS-CoV-2. It is imperative to focus on the available antimicrobial and adjunct therapies during the current emergency state and overcome the challenges associated with the absence of robust controlled studies. There is no established set of drugs to manage SARS-CoV-2 infected patients. However, closely following patients' conditions and responding with the dosage guidelines of available drugs may significantly impact our ability to slow down the infection. Of note, it depends upon the condition of the patients and associated comorbid; therefore, the health workers need to choose the drug combinations judiciously until COVID-19 specific drug or vaccine is developed with the collective scientific rigor. In this article, we reviewed the available antimicrobial drug, supportive therapies, and probable high importance vaccines for the COVID-19 treatment.
由传染性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒病（COVID-2019）近期爆发，这凸显了需要替代疗法来减轻和缓解这种致命感染。这些替代疗法在感染初期开始使用时是有效的。一些曾用于先前其他相关感染（2003年SARS-CoV和2012年中东呼吸综合征冠状病毒（MERS-CoV））的药物可能对当前出现的SARS-CoV-2具有潜在活性。在缺乏针对SARS-CoV-2的任何特异性疗法的情况下，这一事实为当前的干预措施提供了一些理论依据。在当前紧急状态下，必须关注现有的抗菌和辅助疗法，并克服因缺乏强有力的对照研究而带来的挑战。目前尚无一套既定的药物来治疗SARS-CoV-2感染患者。然而，密切关注患者病情并按照现有药物的剂量指南进行应对，可能会显著影响我们减缓感染的能力。值得注意的是，这取决于患者的病情和相关合并症；因此，在以集体科学严谨性研发出针对COVID-19的特异性药物或疫苗之前，医护人员需要谨慎选择药物组合。在本文中，我们综述了用于COVID-19治疗的现有抗菌药物、支持性疗法以及可能具有高度重要性的疫苗。
